For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
According to latest analysis by Gen Consulting Company, the global idiopathic pulmonary fibrosis market is poised to grow by USD 2.0 billion during 2022-2028, progressing at a CAGR of 7.5% during the forecast period.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global idiopathic pulmonary fibrosis market. It traces the market's historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the idiopathic pulmonary fibrosis industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the drug type, action mode, end user, and region. The global market for idiopathic pulmonary fibrosis can be segmented by drug type: Nintedanib, Pirfenidone, others. The Nintedanib segment held the largest share of the global idiopathic pulmonary fibrosis market in 2021 and is anticipated to hold its share during the forecast period. Idiopathic pulmonary fibrosis market is further segmented by action mode: antifibrotic agent, tyrosine kinase inhibitor, other. Globally, the tyrosine kinase inhibitor segment made up the largest share of the idiopathic pulmonary fibrosis market. Based on end user, the idiopathic pulmonary fibrosis market is segmented into: hospital and clinic, others. The hospital and clinic segment was the largest contributor to the global idiopathic pulmonary fibrosis market in 2021. On the basis of region, the idiopathic pulmonary fibrosis market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America is estimated to account for the largest share of the global idiopathic pulmonary fibrosis market.
Market Segmentation
By drug type: Nintedanib, Pirfenidone, others
By action mode: antifibrotic agent, tyrosine kinase inhibitor, other
By end user: hospital and clinic, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The global idiopathic pulmonary fibrosis market report offers detailed information on several market vendors, including Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, FibroGen Inc., Horizon Therapeutics Public Limited Company, Jubilant Pharma Limited, MediciNova Inc., Merck & Co. Inc., Roche Holding AG, United Therapeutics Corporation, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.
Scope of the Report
- To analyze and forecast the market size of the global idiopathic pulmonary fibrosis market.
- To classify and forecast the global idiopathic pulmonary fibrosis market based on drug type, action mode, end user, region.
- To identify drivers and challenges for the global idiopathic pulmonary fibrosis market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global idiopathic pulmonary fibrosis market.
- To identify and analyze the profile of leading players operating in the global idiopathic pulmonary fibrosis market.
Why Choose This Report
- Gain a reliable outlook of the global idiopathic pulmonary fibrosis market forecasts from 2022 to 2028 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.